Skip to main content
Equibles

Marcus Jensen

Innate Pharma SA (IPHA)

Equibles does not estimate personal net worth.

Get an email with a short summary when Innate Pharma SA publishes a filing, an earnings call transcript or a press release.

Get IPHA alerts

About Marcus Jensen

Marcus Jensen has spoken on 2 earnings calls across 1 company, most recently for Innate Pharma SA on November 5, 2026. Innate Pharma SA is classified in the Biotechnology industry within the Healthcare sector.

Marcus Jensen on recent calls

“From a clinical and regulatory perspective, this slide summarizes the projected roadmap for Telomac-3. The Phase 3 study has been initiated with first patient dosing expected in Q1, 2027.”
Other, Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update ·
“Lekwutamap is now progressing towards Phase 3 telemark initiation and planned accelerated approval filing. So from a regulatory and development perspective, the path forward is well-defined.”
Other, Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update ·

Affiliation history

Company network

Recent activity